Prostatype Genomics announced that the retrospective multicentre study in Spain with the Company's gene test Prostatype®?, which includes 126 patients with prostate cancer at seven hospitals and is coordinated by the Spanish National Urology Association, has now been completed with strong positive results. The final results show that the treatment plan could have been modified for 39% of the patients if Prostatype®? had been used as a decision basis at the time of diagnosis.

Prostatype®? was launched in Spain in 2023, and Prostatype Genomics now see good conditions to facilitate a broader use of the product and thus increase sales in this market. In addition to showing that usage of Prostatype®?

at the time of diagnosis would have prompted reclassification of 39% of the patients, the study also showed the following: Prostatype®? can predict progression, predict which of the patients that need curative treatment immediately upon diagnosis and who are therefore not suitable for active monitoring. Prostatype®?

confirms the cases in which it may be appropriate to postpone curative treatment for some men with low-risk prostate cancer. The results from the study will, as previously communicated, be presented at the annual meeting of the Spanish National Urology Association in Santander in April 2024. Based on the very positive results, the Spanish National Urology Association and Prostatype Genomics have decided to continue the study and make it more comprehensive.

Completion is expected in 2024.